FDA Plans Testing for Medical Device Communication Clarity
Published Date: 5/11/2026
Notice
Summary
The FDA is asking for public comments on their plan to keep testing how they communicate about medical devices and radiation products. This helps them make sure their messages reach patients, caregivers, and healthcare pros clearly and effectively. Comments are due by June 10, 2026, and this review won’t cost anyone extra but will improve important health info.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA Will Test Device Communication
The FDA’s Center for Devices and Radiological Health will collect information to test and improve messages about medical devices and radiation-emitting products using interviews, focus groups, surveys, and other research methods so messages better reach patients, caregivers, and health professionals.
Participation Time Burden Estimated
FDA estimates the studies will involve 9,124 total respondents with an average burden of 16 minutes per respondent (range 5 to 90 minutes) and a total annual respondent burden of 2,391 hours across activities.
No Monetary Costs To Respondents
FDA states there are no capital costs or operating and maintenance costs associated with this information collection, meaning respondents will not incur those types of expenses from participating.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2026-09243, Certain Photodynamic Therapy Systems, Components Thereof, and Pharmaceutical Products Used in Combination With the Same; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Termination of the Investigation
The U.S. International Trade Commission found that some photodynamic therapy devices and related products imported by certain companies broke patent rules. To fix this, they’re blocking these products from entering the U.S. without permission and ordering the companies to stop selling them. This means affected businesses must act fast or face legal and financial consequences.
Next: 2026-09245, World Trade Center Health Program; Petitions 032, 033, and 068-Peripheral Neuropathy; Finding of Insufficient Evidence
The World Trade Center Health Program reviewed requests to add peripheral neuropathy as a covered health condition but found not enough proof to do so. This means people affected by 9/11 won’t see changes to their benefits for this condition right now. The decision was made official on May 11, 2026, with no new costs or coverage updates planned.